Dendritic cells (DC) are highly specialised, bone marrow (BM)-derived antigen-presenting cells (APC) that initiate and regulate immune responses. They provide costimulatory signals (in particular, CD40 and the CD28 ligands CD80 and CD86) necessary for naive T cell activation. Functional expression of CD80 and CD86 is blocked by the fusion protein cytotoxic T lymphocyte antigen 4-immunoglobulin (CTLA4Ig), that promotes tolerance induction in animals. Here, replicating mouse (B10; H2 b ) myeloid DC progenitors, were retrovirally transduced to express CTLA4Ig using the centrifugal enhancement method. Gene product was detected by immunocyto-or histochemistry. Maximal DC transduction efficiency was 62%. Compared with control, zeomycin-resistance gene (Zeo)-transduced DC, CTLA4Ig-expressing cells showed markedly impaired capacity to stimulate naive allogeneic (C3H; H2 k ) T cell proliferation and cytotoxic T lymphocyte (CTL) generation. Their ability to induce alloantigen-specific T cell hyporesponsiveness was
Introduction
Dendritic cells (DC) are rare, ubiquitously distributed, bone marrow (BM)-derived professional antigen (Ag)-presenting cells (APC) , that play critical roles in the initiation and modulation of immune responses. [1] [2] [3] [4] They exist as immature cells in non-lymphoid tissues, such as the skin 5 or airway mucosa, 6 where they capture and process foreign and self-Ag. DC that acquire Ag in the periphery migrate to secondary lymphoid tissue where they present antigenic peptides to T cells, express high levels of costimulatory molecules, and initiate immune responses. 1, 7 DC that traffick from organ grafts, such as the heart, 8 or kidney, 9 appear to be the principal instigators of transplant rejection. 7 On the other hand, it has been suggested that immature, donor-derived DC trafficking from the liver, a potential hematopoietic organ, [10] [11] [12] Correspondence: AW Thomson reversed by exogenous IL-2 in secondary mixed leukocyte reactions (MLR). Following local (s.c.) transfer to allogeneic recipients, the genetically modified DC trafficked to T cell areas of draining lymphoid tissue, where transgene expression was detected. Ex vivo analysis of proliferative and CTL responses revealed donor-specific inhibition of alloimmune reactivity by the CTLA4Ig-transduced DC. This effect was associated with marked inhibition of interferon (IFN)-␥ production, but significant augmentation of IL-4 and IL-10 secretion. Thus, retroviral transduction of DC permits in vivo delivery of CTLA4Ig to the precise microenvironment where antigen (Ag) presentation occurs. Comparatively nonimmunogenic retroviral vectors, that allow permanent transgene expression in DC, and promote localized delivery of the immunosuppressive transgene product, promote immune deviation and Ag-specific T cell hyporesponsiveness. Gene Therapy (2000) 7, 1265-1273.
may contribute towards the development of donorspecific transplant tolerance. [13] [14] [15] Recently, it has been shown that costimulatory molecule-deficient, immature DC can induce Ag-specific T cell anergy, 16 and prolong allograft survival. [17] [18] [19] This tolerogenic effect can be potentiated by the costimulation blocking agent anti-CD40 ligand (CD154) mAb, 20 or by administration of T cell-directed monoclonal antibody (mAb). 21 Alternative approaches to the potentiation of DC tolerogenicity include exposure of the cells to the anti-inflammatory cytokines interleukin (IL)-10 22, 23 or transforming growth factor ␤ (TGF-␤), 20 or to the fusion protein cytotoxic T lymphocyte Ag-immunoglobulin (CTLA4Ig). 24, 25 CTLA4Ig binds to the B7 costimulatory molecules CD80 and CD86 on APC, 26 and competitively inhibits B7-CD28-mediated T cell costimulation. 27, 28 Its systemic administration suppresses allograft rejection, 29, 30 and can promote the induction of transplant tolerance. 31 Genetic modification of DC to express either CTLA4Ig or other immunosuppressive molecules, offers a novel approach to the regulation of allo-or autoimmunity. 32 Migration of such genetically engineered DC, adminis-tered either locally or systemically, to interact with Agspecific T cells, may promote tolerance induction, with minimization of the undesired systemic effects of the transgene product. Transduction of DC to express a variety of immunomodulatory transgene products, that either augment 33, 34 or impair T cell responses, [35] [36] [37] has recently been demonstrated. Adenoviral gene delivery achieves high transduction efficiency in non replicating cells, but may be associated with the induction of antiviral immune responses, that limit the efficacy of subsequent doses of the transduced DC. Retroviral vectors are less immunogenic, and allow integration of the exogenous sequence into the genome of replicating cells. This capacity to permit permanent transgene expression may prove valuable where long-term therapeutic gene expression may be required, as in organ or pancreatic islet cell transplantation.
Recently, Takayama et al 35 reported a procedure to obtain high transduction efficiency of replicating myeloid DC progenitors, using retroviral vectors. In this study, we have used the same approach to show that retrovirally transduced myeloid DC expressing CTLA4Ig exhibit impaired capacity to induce allogeneic T cell proliferation and CTL generation. More significantly, these DC induce alloAg-specific T cell hyporesponsiveness, both in vitro and in vivo, and skew the balance of host T helper (Th) cell cytokine production towards Th2 predominance. Thus, genetically modified DC expressing CTLA4Ig have potential for in vivo modulation of alloimmune reactivity, in conjunction with highly targeted delivery of the immunosuppressive transgene product.
Results
Transduction efficiency and transgene expression in CTLA4Ig-transduced DC Replicating granulocyte-macrophage colony-stimulating factor (GM-CSF) + IL-4-stimulated DC progenitors grown from B10 mouse BM were transduced on days 2, 3 and 4 of culture using retroviral supernatant and the centrifugal enhancement method, as described in Materials and methods. To determine transduction efficiency, an MFGenhanced green fluorescent protein (EGFP) retroviral vector encoding the marker gene EGFP was used. Transgene expression (fluorescence) was determined by flow cytometric analysis on day 6 of culture. In several experiments, a maximal transduction efficiency of 62% was achieved (range 40-62%). To determine expression of the transgene product CTLA4Ig, intracellular staining of cytocentrifuge preparations using anti-CTLA4 mAb was performed. As shown in Figure 1a and b, cytoplasmic CTLA4 expression was detected in a high incidence (approximately 50%) of CTLA4Ig-transduced DC on day 6 of culture, 48 h after the final transduction. Two-color flow cytometric analysis of gated CD11c + cells (DC) performed at the same time showed no significant effect of CTLA4Ig gene transfer on surface expression of MHC class II (IA b ) or costimulatory molecules (CD80 and CD86) ( Table 1) .
CTLA4Ig-transduced DC exhibit impaired capacity to induce either allogeneic T cell proliferation or CTL generation We then examined the responses of naive, allogeneic T cells to the genetically engineered DC. Figure 2a shows that CTLA4Ig-transduced DC, harvested on day 6 of culture, exhibited markedly reduced allostimulatory activity in 3-day primary MLR, compared with control genetransduced DC. Zeomycin resistance gene (Zeo)-transduced DC (controls), were potent stimulators of allogeneic T cell proliferation, with progressive increases in thymidine incorporation as DC:T cell ratios increased. By contrast, the allostimulatory activity of CTLA4Ig-transduced DC was markedly inferior, reflecting production of the immunosuppressive gene product by the transduced DC. As shown in Figure 2b , CTLA4Ig transduction also significantly reduced the capacity of the DC to induce the generation of CTL compared with control gene-transduced DC.
CTLA4Ig-transduced DC induce alloAg-specific T cell hyporesponsiveness To determine whether CTLA4Ig-transduced B10 DC could induce allogeneic T cell hyporesponsiveness, freshly isolated C3H T cells were first co-cultured with CTLA4Ig-transduced DC (day 6 of culture) or control (Zeo-transduced) DC in primary MLR. After 72 h, the T cells were harvested, purified, then rested for 36 h. They were restimulated with either B10 (allogeneic), DBA/2 (third-party), or C3H (syngeneic) bulk splenocytes, and proliferative responses determined, as described in Materials and methods. As shown in Figure 3 , T cells exposed initially to CTLA4Ig-transduced B10 DC showed significantly reduced responses upon challenge with B10 Ag compared with T cells stimulated initially with Zeotransduced (control) DC (Figure 3a ). Responses to third party stimulators were not affected significantly ( Figure  3c ). This specific hyporesponsiveness induced by CTLA4Ig-transduced DC was reversed by the addition of IL-2, a cytokine that has been shown to overcome anergy, at the time of T cell restimulation (Figure 3b) . Furthermore, as is evident in Figure 4 , T cells exposed initially to CTLA4Ig-transduced DC exhibited significantly reduced capacity (Ag-specific) for CTL generation in secondary MLR compared with control gene-transduced DC. These results indicated that the T cell hyporesponsiveness induced by CTLA4Ig-transduced DC was alloAg-specific and due to the induction of anergy.
In vivo migration of CTLA4Ig transduced DC into allogeneic recipients
To analyze the capacity of transduced DC to migrate to lymphoid tissue of allogeneic recipients, either 6 × 10 ) that homed to the popliteal lymph node, it was possible to detect the expression of the transgenic CTLA4 by double immunofluorescence labeling ( Figure  1c , upper right inset). Very few donor DC were detected in the periarteriolar lymphocytic sheath of the spleen (data not shown).
Figure 1 (a and b) Expression of transgenic CTLA4-Ig in DC transduced with recombinant retrovirus. Cytospin preparations of Zeo-transduced DC (a) and CTLA4-Ig-transduced DC (b). Expression of transgenic CTLA4-Ig was detected by immunofluorescence (positive cells in red) exclusively in the cytoplasm of CTLA4Ig-transduced DC. Cell nuclei were counterstained with DAPI (immunofluorescence, ×200). (c) Tissue trafficking of CTLA4Ig-transduced (B10) DC into popliteal lymph nodes of allogeneic (C3H) recipients. Either 6 × 10 5 CTLA4Ig-transduced or control Zeo-transduced B10 DC were injected s.c. into the hind footpad of C3H mice. Two days later, popliteal lymph nodes were removed and the presence of donor DC determined by two-color immunohistochemistry. Donor DC were detected with anti-IA b mAb followed by ABC-AP staining (positive cells in blue). T cells were detected with anti-mouse CD3 mAb followed by ABC-Px (positive cells in brown). Donor CTLA4Ig-transduced DC (some indicated by arrows) homed to T cell-dependent areas of draining lymph nodes (in brown) (×100). Lower-right inset: detail of a donor DC expressing IA b (in blue) at higher magnification (×400). Upper-right inset: detail of a donor CTLA4Ig-transduced (B10) DC after homing to a popliteal lymph node of an allogeneic (C3H) recipient. The donor DC coexpresses the transgenic CTLA4Ig (in red) and the donor MHC class II (IA b , originally in green, but seen as yellow as a result of overlap with CTLA4 staining in red). Cell nuclei were counterstained in blue with DAPI (×400).
In vivo administration of CTLA4Ig-transduced DC results in alloAg-specific suppression of T cell responses We next assessed the influence of in vivo administration of CTLA4Ig-transduced DC on allogeneic T cell responses. Following s.c. footpad injection of 6 × 10 5 DC,
Gene Therapy ex vivo proliferative and CTL activities of draining (popliteal) lymph node lymphocytes to donor-specific and third-party alloAgs were examined. As shown in Figure 5 , lymph node lymphocytes exposed initially to CTLA4Ig-transduced DC in vivo and harvested 7 days later, exhibited profound inhibition of proliferative responses to donor, but not to third-party alloAgs. Moreover, as is evident in Figure 6 , T cells exposed initially to CTLA4Ig-transduced DC in vivo showed reduced CTL responses to donor but not third-party alloAgs compared with T cells exposed initially to control (Zeo)-transduced DC. These data clearly indicate that, as in vitro, the hyporesponsiveness of T cells primed with CTLA4Ig-transduced DC in vivo, was Ag-specific.
In vivo administration of CTLA4Ig-transduced DC skews allogeneic T cell responses towards Th2 predominance It has been reported that deviation from Th1 to Th2-type responses may underlie the capacity of CTLA4Ig to prolong allograft survival. [38] [39] [40] We therefore examined the cytokine profiles of draining (popliteal) lymph node lymphocytes from mice injected s.c. in one hind footpad with CTLA4Ig-transduced DC. When compared with those from animals given control (Zeo)-transduced DC, lymphocytes from mice given CTLA4Ig-transduced DC exhibited markedly reduced production of IFN-␥, but enhanced secretion of IL-4 and IL-10 in response to restimulation with allogeneic splenocytes (Figure 7 ). These results indicate that CTLA4Ig-transduced DC can skew the balance of host allogeneic T cell responses to Th2 predominance.
Figure 2 Proliferative (MLR) and cytotoxic (CTL) responses elicited by

Discussion
In this study, we have demonstrated that retrovirally transduced myeloid DC expressing the immunosuppressive fusion protein CTLA4Ig, exhibit reduced capacities to induce allogeneic T cell proliferative and CTL responses. Moreover, these genetically engineered DC induce alloAg-specific T cell hyporesponsiveness, both in vitro and in vivo. Interestingly, as shown in Table 1 , CTLA4Ig transduction did not reduce surface expression of CD80 and CD86 molecules on the cultured DC, as determined by mAb staining and flow cytometry. This may reflect differences in binding/recognition sites on the costimulatory molecules for CTLA4Ig and the CD80/CD86-specific mAbs. As has been reported for CTLA4Ig protein administration, CTLA4Ig-transduced DC suppressed IFN-␥ production and skewed the balance of Th cell responses toward Th2-type cytokine (IL-4 and IL-10) predominance. To our knowledge, this is the first report of the induction of (allo) Ag-specific T cell anergy in vivo using genetically modified APC.
) into one hind footpad of unmodified C3H recipients and 7 days later, draining popliteal lymph node lymphocytes were isolated and restimulated with various numbers of ␥-irradiated allogeneic (B10) bulk splenocytes in 72 h MLR. The cytotoxic activity of the T cells was then determined against allogeneic (EL4) or third-party (P815) targets in 4 h
There is ample evidence that DC are the primary instigators of naive T cell activation, and that they may determine the balance between tolerance and immunity.
1-4,41,42
The potential of these rare BM-derived APC to act as natural immunologic adjuvants has provided the basis for the evaluation of DC-based vaccines, including genetically engineered DC, for anticancer therapy. 33, 34 On the other hand, DC appear to play important roles in central and peripheral tolerance. 2, 41, 42 Thus, DC are instrumental in the induction of intrathymic self-tolerance. 43, 44 It has also been postulated that thymic DC, trafficking to the periphery, may be involved in the development of systemic tolerance following intrathymic Ag injection. 45 In addition, there is evidence that immature or costimulatory molecule-deficient DC can induce allospecific T cell hyporesponsiveness, 16, 21 and prolong pancreatic islet, 17 or cardiac graft survival. [18] [19] [20] [21] However, the efficacy of this approach to the prevention of transplant rejection is transient, due probably to the eventual up-regulation of costimulatory pathway interaction between the adoptively transferred DC and host T cells. In an attempt to overcome this limitation, we sought to block functional expression of CD80/CD86 costimulatory signals by transgene expression at the sites of interaction between allogeneic DC and host T cells in vivo, using CTLA4Ig-transduced DC as potential tolerogenic APC. It has already been demonstrated that DC exposed to immunosuppressive molecules, such as IL-10, viral IL-10, or TGF␤, have impaired allostimulatory activity and the capacity to induce Ag-specific T cell hyporesponsiveness in vitro. 20, 22, 23, 35 Moreover, exposure of mature myeloid DC to CTLA4Ig markedly enhances their capacity to induce apoptosis of alloactivated T cells. 24 
Adenoviral
Gene Therapy delivery of CTLA4Ig to DC also confers tolerogenic properties on these cells in vitro. 37 Gene therapy of graft rejection or autoimmune disease is at an early stage of development, and a variety of gene transfer technologies are under investigation. [46] [47] [48] The use of adenoviral vectors has already been well-documented, and with respect to transduction efficiency, it appears a most effective method to deliver foreign cDNA into DC. However, transgene expression is comparatively shortlived, and viral protein expression is immunogenic compared with other methods of gene transfer. With retroviral vectors, integration of proviral DNA into the cellular genome leads to permanent modification of the target cell genotype, an advantage where long-term therapeutic gene expression may be required, as in allogeneic cell or organ transplantation. Despite the inferior transduction efficiency associated with retroviral vectors compared with adenoviruses, we applied a protocol to transduce replicating DC using the centrifugal transduction method, and achieved a high, maximal level of retroviral transgene delivery of 62%. A similar high level of retroviral delivery of the gene expressing viral IL-10 to murine replicating myeloid DC progenitors has recently been achieved. 35 It is generally accepted that naive CD4 + T cells require two distinct but synergistic signals for activation to provide help to CD8
Figure 7 In vivo administration of CTLA4Ig-transduced DC skews allogeneic T cell responses towards
+ cytotoxic T cells and to B cells. Signal 1 is Ag-specific, mediated via the TCR, and delivered in the context of donor MHC class II. Signal 2 is the costimulatory signal(s), that is not Ag-specific. The bestcharacterized second signal is delivered via the T cell surface molecule CD28, upon its interaction with its two known ligands, the B7 molecules CD80 and CD86, that are expressed primarily on APC. [26] [27] [28] Recombinant CTLA4Ig, a homologue of CD28, consists of the extracellular domain of CTLA4, linked to the constant region of IgG1. It binds B7 molecules on APC with higher affinity than CD28, and competitively blocks B7-CD28 interaction, inhibits T cell activation and induces T cell hyporesponsiveness. 26 It suppresses immune responses to pancreatic islet and organ allografts, particularly if donor Ag (in the form of hematopoietic cells) is also administered, and promotes tolerance induction. [29] [30] [31] 49, 50 The exact mechanism(s) that mediates the immunosuppressive effect of B7-CD28 blockade in vivo is still unclear. There is evidence that donor BM-derived cells (APC, likely DC) are needed for tolerance induction in cardiac transplantation, and that donor Ag is required for the prevention of chronic rejection in CTLA4Ig-treated, organ-transplanted mice. 49, 50 Persistence of donor cells has also been observed in lymphoid tissues of CTLA4Ig-treated mice bearing long-term grafts.
50 CTLA4Ig treatment appears to inhibit expansion of Ag-reactive cells, block Th1 cytokine secretion, and induce anergy in the residual population. 38 There is also evidence that CTLA4Ig may divert host immune responses toward a Th2 pathway. 39 Newell et al 40 reported recently that blockade of the B7-CD28 pathway had inhibitory effects on CD4
+ but not CD8 + T cells, and that inhibition of CD4 + T cell-mediated allograft rejection might be related to down-regulation of Th1 cytokines, and/or up-regulation of Th2 cytokines. The present findings with CTLA4Ig-gene-transduced DC, including the greater suppression of proliferative compared with cytotoxic T cell responses following exposure to these cells, are compatible with the latter observations. Whether Th2-like cells might actually mediate a tolerant state induced by genetically engineered DC in vivo remains to be determined. In summary, we present evidence that retroviral delivery of the CTLA4Ig gene to replicating progenitors reduces the capacity of myeloid DC to induce allogeneic T cell proliferation and cytotoxicity. In addition, CTLA4Ig-transduced DC induce alloAg-specific T cell hyporesponsiveness, and skew towards Th2-type cytokine predominance. These novel findings indicate that genetically engineered DC expressing CTLA4Ig may offer therapeutic potential for highly targeted suppression of T cell-mediated immune responses, such as allograft rejection, or autoimmune disease, with reduced risk of the untoward effects of systemic protein or transgene administration. Male C57BL/10J (B10; H2 b ), C3H/HeJ (C3H; H2 k ) and DBA/2 (H2 d ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), and used as a source of BM or spleen cells at 8-12 weeks of age. The animals were housed in the specific pathogen-free facility of the University of Pittsburgh Medical Center.
Materials and methods Mice
Retroviral vectors
The cDNA encoding the reporter gene product EGFP was subcloned from the plasmid pEGFP-N1 (Clontech, Palo Alto, CA, USA) into the retroviral proviral plasmid MFG to generate MFG-EGFP. The Zeomycin resistance gene (Zeo) was subcloned into MFG to construct MFG-Zeo. The cDNAs encoding mouse (m) CTLA4Ig and an IRESZeo cassette were both subcloned into MFG to prepare DFG-mCTLA4Ig-Zeo. The plasmids MFG-EGFP, MFGZeo and DFG-mCTLA4Ig-Zeo were transfected into the BOSC 23 ecotropic packaging cell line to obtain supernatant containing recombinant (r) retrovirus encoding EGFP, Zeo, or mCTLA4Ig + Zeo (CTLA4-Ig), respectively.
Propagation and retroviral transduction of DC Myeloid DC were propagated in vitro using procedures described elsewhere in detail. 35 In brief, BM cells were harvested from femurs of normal B10 mice, and depleted of lymphocytes with a mAb cocktail comprising anti-B220 (RA3-3A1/6.1), anti-Lyt 2 (2.43) and anti-L3T4 (GK1.5) (each generated from hybridomas provided by the American Type Culture Collection, Rockville, MD, USA) and rabbit complement (Accurate Chemical and Scientific, Westbury, NY, USA). The cocktail-depleted BM cells were then cultured overnight in RPMI-1640 (Life Technologies, Gaithersburg, MD, USA) supplemented with antibiotics, and 10% v/v heat-inactivated fetal bovine serum (FBS). The non-adherent cells were removed carefully and replated with 4 ng/ml r GM-CSF and 1000 units (U)/ml r m IL-4 (each cytokine from the Schering Plough Research Institute, Kenilworth, NJ, USA). Retroviral transduction was performed using the centrifugal enhancement method. 51 Thus, replicating DC progenitors were harvested on day 2, and 10 6 cells suspended in 1 ml of retroviral supernatant with 4 ng/ml GM-CSF, 1000 U/ml IL-4, and 8 mg/ml polybrene (Sigma Chemical, St Louis, MO, USA), then centrifuged at 2500 g for 2 h. The transduction process was repeated on days 3 and 4, and the cells harvested on day 6.
Flow cytometry
Cell surface expression of MHC class II and costimulatory molecules on cultured DC was determined by twocolor mAb staining and flow cytometric analysis, as described. 35 The cells were labeled with phycoerythrinconjugated anti-CD11c mAb and fluorescein isothyocyanate-conjugated anti-IA b , CD80, or CD86 (PharMingen, San Diego, CA, USA). Mean fluorescence intensity for each molecule of interest was determined on gated CD11c
+ cells using an EPICS Elite flow cytometer (Coulter, Hialeah, FL, USA).
Detection of CTLA4Ig production by transduced DC in vitro Production of CTLA4Ig by the genetically modified DC in vitro was detected by immunofluorescence staining of cytospin preparations. Briefly, CTLA4Ig-or Zeo-transduced DC were harvested from culture wells and spun on to glass slides using a Shandon cytocentrifuge (230 g for 5 min). Slides were air-dried, fixed in cold (4°C) acetone for 5 min and stored until use. For immunolabeling, the cytospins were incubated successively with: (1) normal goat serum; (2) avidin blocking solution (Vector, Burlingame, CA, USA); (3) optimal concentration (dilution 1:100) of hamster anti-mouse CD152 (CTLA4) mAb (clone UC10-4F10-11; PharMingen); (4) biotin-conjugated mouse anti-hamster IgG (cocktail) mAb (dilution 1:100, clones G70-204 and G94-56); and (5) Cy3-conjugated streptavidin (dilution 1:2500, Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Cell nuclei were counterstained with 4Ј, 6 diamidino-2-pheylinolole (DAPI; Molecular Probes, Eugene, OR, USA).
Mixed leukocyte reaction (MLR)
The ability of DC to stimulate freshly isolated, naive allogeneic T cells was determined in primary MLR. Normal C3H splenic T lymphocytes were purified by passage through nylon wool columns (30 min; 37°C). They were cultured with various numbers of allogeneic, ␥-irradiated CTLA4Ig-or control gene (Zeo)-transduced, or unmodified B10 DC in 96-well, microculture plates for 72 h. For the final 16 h of culture, 1 Ci −3 H-TdR was added to each well. The cultures were harvested on to glass fiber filter disks, using a multiple cell harvester, and thymidine incorporation quantified using a liquid scintillation counter.
Cytotoxic T lymphocyte (CTL) assay
Allogeneic, ␥-irradiated, CTLA4Ig-or Zeo-transduced (control) B10 DC were cultured with freshly isolated T cells from normal C3H mice (ratio 1:20) for 5 days, then used as cytotoxic effectors, as described. 35 The EL4 lymphoma (H2 b ) and the P815 cell line (H2 d ) were used as sources of specific and third party targets, respectively; 10 6 cells were labeled with 100 Ci of Na 2 51 Cr O 4 . The percentage of specific 51 Cr release was determined after incubating effector and target cells at various ratios for 4 h at 37°C in RPMI-1640 + 10% FBS in 5% CO 2 in air. Maximum 51 Cr release was determined by osmotic lysis of the target cells. The percent specific cytotoxicity was calculated using the following formula: % cytotoxicity = 100 × (experimental (c.p.m.) − spontaneous (c.p.m.)/maximum (c.p.m.) − spontaneous (c.p.m.)). The results are expressed as means ± 1s.d. of % specific 51 Cr release in triplicate cultures.
Induction of T cell hyporesponsiveness
The capacity of the retrovirally transduced DC to induce alloAg-specific T cell hyporesponsiveness was assessed as described, 16 with minor modifications. Two × 10 6 freshly isolated, allogeneic (C3H) T cells were co-cultured initially with 10 6 ␥-irradiated, CTLA4Ig-or Zeo-transduced B10 DC. Seventy-two hours later, the cultures were harvested and the T cells separated using lymphocyte M (Cedarlane, Ontario, Canada), then rested for 36 h. They were restimulated with ␥-irradiated, bulk splenocytes from either the same (B10) donor strain, or from thirdparty (DBA/2; specificity control), or syngeneic (C3H) controls. R human IL-2 (20 U/ml; Life Technologies) was added at the start of some of these cultures to test for reversal of hyporesponsiveness (anergy). Seventy-two Gene Therapy hours later, T cell proliferation was measured by thymidine incorporation. The restimulated T cells recovered from the secondary MLR were used as effectors in CTL assays, as described above.
Immunohistochemical analysis of DC trafficking in allogeneic hosts
Analysis of tissue trafficking of retrovirally transduced B10 DC in allogeneic C3H recipients, was performed 2 days after the cells were administered s.c. (6 × 10 5 ) into the hind footpad. Popliteal lymph nodes and spleens were removed, embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN, USA), snap frozen in chilled isopentane and stored at −80°C until use. Eight m cryostat sections were mounted on slides treated with Vectabound (Vector) air-dried, and fixed in cold acetone (4°C) for 10 min. For detection of donor (B10) DC in T cell areas of host lymphoid tissue, sections were incubated successively with: (1) normal goat serum; (2) avidin blocking solution (Vector); (3) optimal concentration (1:100) of biotinconjugated mouse anti-IA b ␤ chain mAb (clone 25-9-17, PharMingen); (4) avidin-biotin complex, alkaline phosphatase (ABC-AP; Vector); (5) optimal concentration (1:100) of hamster anti-mouse CD3⑀ (clone 145-2C11, PharMingen); (6) biotin-conjugated mouse anti-hamster IgG (cocktail) mAb (dilution 1:100; clones G70-204 and G94-56, PharMingen); and (7) avidin-biotin complex, peroxidase (ABC-Px; Vector). Endogenous AP activity was inhibited by addition of levamisole (Vector) in the substrate solution. Endogenous peroxidase activity was blocked by successive incubations in: 70% ethanol, 1% H 2 O 2 methanol, and 70% ethanol. Tissue sections were mounted first in Crystal/mount (Biomeda, Foster City, CA, USA), and then in Permount (Fisher Scientific, Pittsburgh, PA, USA). Hamster or mouse irrelevant Igs of the same isotype as the primary mAb were used as controls.
Visualization of CTLA4Ig production by trafficking DC in allogeneic hosts Production of transgenic CTLA4Ig by allogeneic, retrovirally transduced DC that homed in vivo to recipient lymph nodes was detected by double immunofluorescence staining of cryostat sections. Briefly, after blocking with goat serum and avidin blocking solution as described, the sections were incubated successively with: (1) FITC-conjugated mouse anti-IA b ␤ chain mAb (1:50, clone 25-9-17, PharMingen) and hamster anti-mouse CD152 (CTLA4) mAb (1:100) clone UC10-4F10-11, PharMingen); (2) biotin-conjugated mouse anti-hamster IgG (cocktail) mAb (dilution 1:100, clones G70-204 and G94-56, PharMingen); and (3) Cy3-conjugated streptavidin (dilution 1:3000, Jackson ImmunoResearch Laboratories). Cell nuclei were counterstained with DAPI. 
